Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

摘要: Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. The standard treatment advanced stage combination optimal debulking surgery and platinum-based chemotherapy. Nevertheless, recurrence frequent (around 70%) prognosis globally poor. New therapeutic agents are needed to improve survival. Since EOC strongly immunogenic, immune checkpoint inhibitors under evaluation their capacity contrast "turn off" signals expressed by tumor escape system usually responsible self-tolerance maintenance. This article reviews literature on anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-PD-1, anti-PD-L1, anti-PD-L2 antibodies in highlights possible lines development. Further studies better define prognostic role inhibitors, identify predictors response clinical setting EOC.